Diabetes Care 41 , 333340 (2018)
So Whats Wrong With Pharmaceuticals
Step 3 The Deception: In the best case scenario, customers receive actual product, but its of questionable quality and effectiveness
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist [type 2 diabetes trial]
8.4 Clinical differentiation in a post-GLP-1 landscape The success of incretin-based therapies has raised expectations for efficacy in metabolic disease, particularly in obesity, where benchmarks for weight loss and cardiometabolic improvement are now well established (Kushner and Kahan, 2024)
The testing showed the vial had a 16.6 per cent purity, and the lab that did the testing advised the rest was likely to be "fill material", including substances such as mannitol, a sugar that stabilises and protects the active ingredients